News AZ extends cardiovascular pipeline with $2bn CSPC deal AstraZeneca has joined the ranks of pharma companies seeking to bring drugs targeting lipoprotein(a) to market, paying $100 million upfront for rights to a drug developed by CSPC Pharmaceut
Sales & Marketing Sponsored Global reach, personal touch: Mastering customer engagement ... In today's interconnected pharma market, the ability to scale engagement across borders is essential for survival and growth.
